js201
Recombinant proteinexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2021 (NCT04951947)
Timeline
Indications
Mechanism of action
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04956926 | Phase 1 | Jul 29, 2021 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04951947 | Phase 2 | Jun 1, 2021 | Central South University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1